Trial reportJournal of obesity2013
Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus.
Trial report in Journal of obesity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00555958 (VBLOC™ Clinical Trial), which is not on this map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
VBLOC™ Clinical Trial: Vagal Block for Obesity Control
Who cites it
52 citing papers in PubMed.
- Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial.Obesity surgery · 2017Trial
- Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-Related Comorbid Condition: the ReCharge Study.Obesity surgery · 2016Trial
- Sustained Weight Loss with Vagal Nerve Blockade but Not with Sham: 18-Month Results of the ReCharge Trial.Journal of obesity · 2015Trial
- Early experience with customized, meal-triggered gastric electrical stimulation in obese patients.Obesity surgery · 2015Trial
- Vagal nerve innervation divergence in liver/pancreas: A forgotten key to endocrine recovery after transplantation?World journal of transplantation · 2026Review
- Renal nerve stimulation modulates renal blood flow in a frequency-dependent manner.Bioelectronic medicine · 2025Article
- Article
- Renal nerve stimulation modulates renal blood flow in a frequency-dependent manner.Research square · 2025Article
- Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation.Bioelectronic medicine · 2025Review
- Vagal Splenic-Dependent Effects Influence Glucose Homeostasis, Insulin Secretion, and Histopathology of the Endocrine Pancreas in Hypothalamic Obese Male Rats: Vagus Nerve and Spleen Interactions Affect the Endocrine Pancreas.TheScientificWorldJournal · 2025Article
- Central and peripheral neural circuits regulating glucose homeostasis.npj biomedical innovations · 2025Review
- Vagus nerve stimulation (VNS): recent advances and future directions.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2024Review
- Spinal afferent neurons: emerging regulators of energy balance and metabolism.Frontiers in molecular neuroscience · 2024Review
- Stimulation parameters for directional vagus nerve stimulation.Bioelectronic medicine · 2023Article
- Prevalence of excess weight and associated socio-demographic factors among postmenopausal women: A population-based study in Ghana.African journal of primary health care & family medicine · 2023Article
- Impact of Vagotomy on Postoperative Weight Loss, Alimentary Intake, and Enterohormone Secretion After Bariatric Surgery in Experimental Translational Models.Obesity surgery · 2022Article
- Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?Annual review of pharmacology and toxicology · 2022Review
- Molecular mechanisms linking stress and insulin resistance.EXCLI journal · 2022Review
- Impact of the Hepatic Branch of the Vagus Nerve Transection in Laparoscopic Sleeve Gastrectomy for Patients with Obesity and Type 2 Diabetes Mellitus.Obesity surgery · 2021Article
- Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.Reviews in endocrine & metabolic disorders · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn active device that downregulates abdominal vagal signalling has resulted in significant weight loss in feasibility studies.
objectiveTo prospectively evaluate the effect of intermittent vagal blocking (VBLOC) on weight loss, glycemic control, and blood pressure (BP) in obese subjects with DM2.
methodsTwenty-eight subjects were implanted with a VBLOC device (Maestro Rechargeable System) at 5 centers in an open-label study. Effects on weight loss, HbA1c, fasting blood glucose, and BP were evaluated at 1 week to 12 months.
results26 subjects (17 females/9 males, 51 ± 2 years, BMI 37 ± 1 kg/m(2), mean ± SEM) completed 12 months followup. One serious adverse event (pain at implant site) was easily resolved. At 1 week and 12 months, mean excess weight loss percentages (% EWL) were 9 ± 1% and 25 ± 4% (P < 0.0001), and HbA1c declined by 0.3 ± 0.1% and 1.0 ± 0.2% (P = 0.02, baseline 7.8 ± 0.2%). In DM2 subjects with elevated BP (n = 15), mean arterial pressure reduced by 7 ± 3 mmHg and 8 ± 3 mmHg (P = 0.04, baseline 100 ± 2 mmHg) at 1 week and 12 months. All subjects MAP decreased by 3 ± 2 mmHg (baseline 95 ± 2 mmHg) at 12 months.
conclusionsVBLOC was safe in obese DM2 subjects and associated with meaningful weight loss, early and sustained improvements in HbA1c, and reductions in BP in hypertensive DM2 subjects. This trial is registered with ClinicalTrials.gov NCT00555958.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.